<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02909049</url>
  </required_header>
  <id_info>
    <org_study_id>URO - CHUAC - BPSat - 001.</org_study_id>
    <nct_id>NCT02909049</nct_id>
  </id_info>
  <brief_title>Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy</brief_title>
  <official_title>Open Randomized Clinical Trial to Examine Individual Pain Tolerance in the Use of Two Anesthetic Techniques to Perform Saturation Prostate Biopsy</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Complexo Hospitalario Universitario de A Coruña</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Complexo Hospitalario Universitario de A Coruña</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To assess the effectiveness of two anesthetic techniques by measuring the pain through visual
      analog scale (VAS), to obtain saturation prostate biopsies.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To assess the effectiveness of two anesthetic techniques by measuring the pain through visual
      analog scale (VAS), to obtain saturation prostate biopsies.

      Anesthetic technique (control) - Intravenous sedation with Midazolam, Fentanile and Ketamine.

      Anesthetic technique (intervention) - Regional Mepivacaine infiltration of periprostatic
      region.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2016</start_date>
  <completion_date type="Actual">January 24, 2018</completion_date>
  <primary_completion_date type="Actual">January 24, 2018</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in visual analog scale (VAS)</measure>
    <time_frame>1 hour baseline</time_frame>
    <description>Change in visual analog scale (VAS) from baseline and after prostate biopsy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of patients with complications after anesthesic procedure and prostate biopsy procedure, after 24 hours of the procedure and at end of study visit. All units will be measured as numbers.</measure>
    <time_frame>One week</time_frame>
    <description>To assess the safety of the procedure and complications in the use of each of the anesthetic techniques during saturation prostate biopsy. Safety events will be measured during saturation prostate biopsy and after recovery, during 24 hours. Number of patients with complications after anesthesic procedure and prostate biopsy procedure. Number of patients with complications after 24 hours of the procedure. Number of patients with complications at end of study visit.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Prostatic Cancer</condition>
  <arm_group>
    <arm_group_label>CONTROL</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Saturation prostate biopsy under intravenous sedation MIDAZOLAM 1,5 mg per kilogram intravenous, 5 minutes prior to biopsy FENTANILE 0,05 mg per kilogram intravenous, 3 minutes prior to biopsy KETAMINE 0.5 mg per kilogram intravenous, 1 minute prior to biopsy</description>
  </arm_group>
  <arm_group>
    <arm_group_label>EXPERIMENTAL</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Saturation prostate biopsy under local anesthesia MEPIVACAÍNE 2% 10 millimeters periprostatic block at base and ápex, bilaterally.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MIDAZOLAM</intervention_name>
    <description>Intravenous bolus anesthesia 5 minutes previous to saturation prostate biopsy.</description>
    <arm_group_label>CONTROL</arm_group_label>
    <other_name>MIDAZOLAM 15mg/3ml ATC N05CD08 MAN 65319</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MEPIVACAÍNE</intervention_name>
    <description>Local periprostatic anesthesia infiltration, previous to saturation prostate biopsy.</description>
    <arm_group_label>EXPERIMENTAL</arm_group_label>
    <other_name>MEPIVACAINE 2% ATC N01BB03 MAN 62606</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>FENTANILE</intervention_name>
    <description>Intravenous bolus anesthesia 3 minutes previous to saturation prostate biopsy.</description>
    <arm_group_label>CONTROL</arm_group_label>
    <other_name>FENTANILE 0,05 mg/ml ATC N01AH01 MAN 41764</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>KETAMINE</intervention_name>
    <description>Intravenous bolus anesthesia 1 minute previous to saturation prostate biopsy.</description>
    <arm_group_label>CONTROL</arm_group_label>
    <other_name>KETAMINE 50 mg/ml ATC N01AX03 Marketing Authorisation number 47034</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male patient

          -  Persistence of suspected prostate cancer by altering the prostatic specific antigen
             and / or digital rectal examination.

          -  Two previous negative prostate biopsies .

          -  Age &lt; 75 years.

          -  Signature of informed consent to perform prostate biopsy.

          -  Signature of informed consent for the study.

        Exclusion Criteria:

          -  Age &gt; 75 years.

          -  Absence of consent or refusal to the study .

          -  Presence of prostate cancer in previous biopsy observation .

          -  Medical-surgical patient's problems, absolutely contraindicating biopsy under local
             anesthesia.

          -  Presence of any allergies to medications involved in the study .

          -  Patient's clinical situation that does not allow an outpatient operation and aftercare
             required .

          -  Medical condition of the patient, preventing the realization of outpatient biopsy.

          -  No companion.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jose L Ponce, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Complejo Hospitalario Universitario A Coruña</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Jose Luis Ponce Diaz-Reixa</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <verification_date>January 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 19, 2016</study_first_submitted>
  <study_first_submitted_qc>September 19, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2016</study_first_posted>
  <last_update_submitted>January 25, 2018</last_update_submitted>
  <last_update_submitted_qc>January 25, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">January 26, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Complexo Hospitalario Universitario de A Coruña</investigator_affiliation>
    <investigator_full_name>José Luis Ponce Díaz-Reixa</investigator_full_name>
    <investigator_title>MD</investigator_title>
  </responsible_party>
  <keyword>Prostate Biopsy</keyword>
  <keyword>Local Anesthesia</keyword>
  <keyword>Pain</keyword>
  <keyword>Biopsy of prostate</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prostatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anesthetics</mesh_term>
    <mesh_term>Ketamine</mesh_term>
    <mesh_term>Midazolam</mesh_term>
    <mesh_term>Mepivacaine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

